Before we get to the details, we want to provide the links: Make your picks at the bracket picking site or The educational content at AJKD Blog Every March, the [...]
“Prediction is very difficult, especially about the future” – Danish Physicist Niels Bohr, also attributed to Yogi Berra, NY Yankees There is something about [...]
Although cardiovascular disease accounts for the largest proportion of deaths in both the chronic kidney disease (CKD) and the dialysis populations, interventions to prevent [...]
Check out all of the coverage of the American Society of Nephrology’s 2015 Kidney Week in San Diego, California, by AJKD Blog’s Matt Sparks, Joel Topf, Edgar Lerma, [...]
This session from #KidneyWk 2015 nicely captured some basic science aspects – starting off at the cellular level, and then transitioned quite smoothly to clinical trials [...]
Note: Tolvaptan is not approved for use in US for Polycystic Kidney Disease, though it is available for that indication in Canada, UK, Japan, and other places. The Canadian [...]
The annual Canadian Hypertension Congress was held from Oct 22-24, 2015 in Toronto. One of the highlights of this conference is the presentation of the Canadian Hypertension [...]
Hypertension Canada’s 5th annual Canadian Hypertension Congress is being held from Oct 22-24, 2015, in Toronto and the AJKD Blog will be providing a [...]
The literature surrounding interventions to improve clinical outcomes in hemodialysis patients is littered with negative trials, be that with dose of dialysis, nocturnal [...]
The association between chronic kidney disease (CKD) and cardiovascular events and death was first promoted by Alan Go over a decade ago. Since then, this association has [...]